## APPENDIX

**Supplementary Table I. Predictors of mortality at two years (n = 274).**

| Predictor | OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|---|---|---|---|---|
| Age | 1.08 (1.05–1.11) | < 0.001 | 1.09 (1.05–1.12) | < 0.001 |
| LVEF* | 0.98 (0.96–0.99) | 0.009 | 0.97 (0.95–0.99) | 0.006 |
| Diabetes mellitus | 2.40 (1.39–4.15) | 0.002 | 2.65 (1.46–4.82) | 0.001 |
| Hypertension | 0.64 (0.23–1.82) | 0.403 | 0.83 (0.26–2.72) | 0.761 |
| Saphenous vein graft | 1.80 (0.61–5.28) | 0.287 | 1.42 (0.45–4.50) | 0.552 |

*Missing data in LVEF was imputed by using the mean LVEF of 237 (45.5%) patients. CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio

**Supplementary Table II. Predictors of major adverse cardiovascular events at two years.**

| Predictor | OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|---|---|---|---|---|
| Age | 1.05 (1.03–1.08) | < 0.001 | 1.06 (1.03–1.08) | < 0.001 |
| Diabetes mellitus | 1.81 (1.10–2.98) | 0.019 | 1.84 (1.07–3.15) | 0.027 |
| LVEF* | 0.98 (0.96–1.00) | 0.103 | 0.99 (0.97–1.01) | 0.190 |
| Hypertension | 0.44 (0.14–1.42) | 0.171 | 0.42 (0.11–1.56) | 0.194 |
| ACS | 0.65 (0.38–1.10) | 0.110 | 0.61 (0.34–1.10) | 0.098 |
| Hyperlipidaemia | 0.64 (0.35–1.18) | 0.155 | 0.67 (0.34–1.29) | 0.230 |
| Smoking | 0.54 (0.26–1.13) | 0.102 | 0.65 (0.29–1.45) | 0.291 |
| Saphenous vein graft | 1.06 (0.36–3.13) | 0.920 | 0.96 (0.30–3.04) | 0.937 |

*Missing data in LVEF was imputed by using the mean LVEF of 237 (45.5%) patients. ACS: acute coronary syndrome; CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio



**Supplementary Fig. 1** Chart shows two-year survival curve of the study population, with mortality rates at one year and two years of 22.6% (n = 62) and 36.5% (n = 100), respectively.

**Kaplan-Meier Plot**
With Number of Subjects at Risk

**Supplementary Fig. 2** Chart shows two-year Kaplan-Meier curve for major adverse cardiovascular events (MACE) stratified by the presence of diabetes mellitus (DM). There was a trend towards lower two-year MACE-free survival in DM compared to non-DM patients, although this relationship was not statistically significant. (two-year MACE-free survival: 39% vs. 54%, p = 0.0670).